TheraCryf (LSE:TCF) Ending Cash Position: £1.46 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is TheraCryf Ending Cash Position?

TheraCryf LSE:TCF Ending Cash Position is £1.46 Mil as of Sep. 2025. The stock has 3 warning signs investors should review.

TheraCryf's Ending Cash Position for the quarter that ended in Sep. 2025 was £1.46 Mil.

TheraCryf's quarterly Ending Cash Position increased from Sep. 2024 (£1.20 Mil) to Mar. 2025 (£2.11 Mil) but then declined from Mar. 2025 (£2.11 Mil) to Sep. 2025 (£1.46 Mil).

TheraCryf's annual Ending Cash Position declined from Mar. 2023 (£5.00 Mil) to Mar. 2024 (£2.00 Mil) but then increased from Mar. 2024 (£2.00 Mil) to Mar. 2025 (£2.11 Mil).

TheraCryf Ending Cash Position Related Terms

TheraCryf Ending Cash Position Historical Data

* Premium members only.

The historical data trend for TheraCryf's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TheraCryf Ending Cash Position Chart

TheraCryf Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.59 4.51 5.00 2.00 2.11

TheraCryf Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.73 2.00 1.20 2.11 1.46

TheraCryf Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

TheraCryf's Ending Cash Position for the fiscal year that ended in Mar. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.004+0.105
=2.11

TheraCryf's Ending Cash Position for the quarter that ended in Sep. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=2.11+-0.655
=1.46

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of £1.46 Mil mean?
TheraCryf (LSE:TCF) has a Ending Cash Position of £1.46 Mil as of Sep. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on TheraCryf and its competitors.
Is TheraCryf's Ending Cash Position too high?
TheraCryf's current Ending Cash Position is £1.46 Mil.
How does TheraCryf's Ending Cash Position compare to VRTX and REGN?
TheraCryf's Ending Cash Position of £1.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on TheraCryf and its competitors. TheraCryf's current Ending Cash Position is £1.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TheraCryf stock overvalued right now?
TheraCryf (LSE:TCF) has a current Ending Cash Position of £1.46 Mil. The current Ending Cash Position is £1.46 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For TheraCryf (LSE:TCF), the current Ending Cash Position is £1.46 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TheraCryf Business Description

Address Congleton Road, Alderley Park, Nether Alderley, Cheshire, GBR, SK10 4TG
TheraCryf PLC is a clinical stage therapeutics company developing therapeutic candidates for behavioural brain disorders such as opioid and alcohol addiction, and acute/chronic fatigue. It focuses on data generation to support potential partnerships for its programs with mid-sized and large pharmaceutical companies. The company's pipeline includes Ox-1 - Substance Use Disorders (SUDs) / Anxiety, DAT - Fatigue and Narcolepsy, SFX-01, and SFX-01- Neurodevelopmental Disorders.